-Moneycontrol.com The coverage under the MGNREGA has consistently increased from 4.51 crore households during 2008-09 to 5.49 crore households during 2010-11 with averaged employment of 47 persondays per household. Average wage has consistently increased from Rs 65 in 2006-07 to Rs. 100 in 2010-11. Women person days have been 48% during the last three years against the stipulation of 1/3 as per the Act. This is stated in Economic Survey 2011-12,...

-The Business Standard   Major subsidies extended by the government are likely to jump to Rs 1,34,411 crore during 2011-12 The Survey has warned of deteriorating fiscal health due to a mounting subsidy burden. The huge outgo over the past year has been largely on account of the global rally in crude oil prices, the fertiliser subsidy and state-controlled foodgrain prices, it said. It also blamed ‘coalition politics and federal considerations’ for holding...

-The Economic Times The NGOs and experts working in water sector have welcomed the idea of promoting private investment in irrigation sector. "There is need and large scope for participation of private sector in the irrigation sector. The success will however will depend upon how the details are worked out taking views of local people and NGOs into consideration," said Dr Madhav Chitale, former secretary, Ministry of Water Resources.  The Finance Minister...

-The Pioneer Hitting at UPA’s biggest flagship scheme Mahatma Gandhi National Rural Employment Guarantee Act (MGNREGA), Agriculture Ministry has criticised the scheme in it’s first ever Agriculture Survey saying that MGNREGA has led to double digit growth in wages annually in the last few years even exceeding the rate of inflation that prevailed during this period. The Agriculture Survey is compiled by the Agriculture Ministry as a precursor to Union Budget on...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...